There is an increased incidence of melanoma in HIV patients compared to the general population. The incidence is 26-28% higher in the pre-HAART era and remains elevated at 26-50% even after the introduction of HAART treatment. While immune deficits associated with HIV increase cancer risks, clinical trials often exclude HIV patients with melanoma. However, treatment of melanoma in HIV patients with a high CD4 count, low viral load, no other illnesses, and slow disease progression may have outcomes similar to HIV-negative patients.